Administration of JTE013 significantly improved post-ischemic angiogenesis and blood flow perfusion in the PAD model, providing a therapeutic target against S1pr2 as a novel strategy to improve revascularization and blood flow recovery for PAD. Here, S1PR2 is linked to peripheral arterial disease.